PUBLISHER: The Business Research Company | PRODUCT CODE: 1815896
PUBLISHER: The Business Research Company | PRODUCT CODE: 1815896
Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Global Market Report 2025
Sphingosine 1 phosphate receptor (S1PR) modulator drugs are a class of therapeutic agents that specifically target sphingosine-1-phosphate (S1P) receptors, a family of G-protein-coupled receptors involved in essential cellular processes. These drugs regulate the activity of S1P receptors, which play a crucial role in immune cell trafficking, vascular function, and inflammation.
The primary types of sphingosine 1 phosphate receptor (S1PR) modulator drugs include fingolimod and ozanimod. Fingolimod is an oral medication used for treating multiple sclerosis (MS) by modulating the immune system to prevent nerve damage associated with the disease. These drugs are available in different routes of administration, including oral, injectable, and topical forms, and are used for treating multiple sclerosis, cardiovascular diseases, and transplant rejection. Their primary end-users include hospitals, rehabilitation centers, and retail pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report is one of a series of new reports from The Business Research Company that provides sphingosine 1 phosphate receptor (S1PR) modulator drugs market statistics, including the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry global market size, regional shares, competitors with the sphingosine 1 phosphate receptor (S1PR) modulator drugs market share, detailed sphingosine 1 phosphate receptor (S1PR) modulator drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the sphingosine 1 phosphate receptor (S1PR) modulator drugs industry. This sphingosine 1 phosphate receptor (S1PR) modulator drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increased investment in autoimmune drug development, expansion of indications, growing awareness of autoimmune disease management, and rising healthcare expenditure.
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing demand for oral therapies over injectables, increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, growth in awareness and diagnosis of conditions like multiple sclerosis, and rising geriatric population prone to autoimmune diseases. Major trends in the forecast period include advancements in receptor selectivity, regulatory approvals for new indications, integration of real-world evidence (RWE), technological advancements in drug delivery, a shift toward oral therapies, strategic collaborations, and acquisitions.
The forecast of 5.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could burden U.S. neurology clinics by driving up prices of fingolimod derivatives and MS relapse prevention therapies manufactured in Switzerland and Japan. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of autoimmune diseases is expected to drive the expansion of the sphingosine 1-phosphate receptor (S1PR) modulator drugs market. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, leading to inflammation and tissue damage. Factors such as genetics, environmental triggers, lifestyle changes, and improved diagnostic capabilities contribute to the growing incidence of these conditions. S1PR modulator drugs help regulate immune cell migration, reducing inflammation in autoimmune diseases such as multiple sclerosis and ulcerative colitis. For example, in May 2024, data published by the National Center for Health Statistics (NCHS), a US-based health statistics agency, indicated that the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes within the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. As a result, the rising prevalence of autoimmune diseases is fueling the growth of the S1PR modulator drugs market.
Leading companies in the S1PR modulator drugs market are emphasizing the development of innovative therapies, such as oral treatments, to improve patient compliance, enhance drug efficacy, and expand the therapeutic potential of these medications in managing autoimmune diseases. Oral therapy involves administering medications in pill or tablet form, providing a convenient and non-invasive treatment option for patients. For instance, in March 2022, Pfizer, a US-based pharmaceutical and biotechnology company, announced positive phase 3 trial results for etrasimod in ulcerative colitis patients. The drug met its primary and key secondary endpoints, demonstrating significant improvements in remission rates, endoscopic outcomes, and symptom relief. These results highlight etrasimod's potential as a new treatment option for moderate-to-severe ulcerative colitis. Pfizer plans to advance regulatory submissions, reinforcing its immuno-inflammatory disease portfolio and commitment to innovative healthcare solutions.
In December 2023, Vanda Pharmaceuticals, a US-based pharmaceutical company, acquired the U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition strengthens Vanda's portfolio by adding an innovative therapy for relapsing multiple sclerosis (MS), a condition with increasing prevalence and a significant unmet medical need. Actelion Pharmaceuticals Ltd., a Switzerland-based biopharmaceutical company, specializes in developing sphingosine 1-phosphate receptor (S1PR) modulator drugs for various diseases.
Major players in the sphingosine 1 phosphate receptor (s1pr) modulator drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvise Pharmaceuticals, Priothera Limited, and Arena Pharmaceuticals.
Asia-Pacific was the largest region in the sphingosine 1 phosphate receptor (S1PT) modulator drugs market in 2024. The regions covered in sphingosine 1 phosphate receptor (S1PR) modulator drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sphingosine 1 phosphate receptor (S1PR) modulator drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The sphingosine 1 phosphate receptor (S1PR) modulator drugs market consists of sales of non-selective S1PR modulators, selective S1PR1 modulators, and next-generation and experimental S1PR modulators. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on sphingosine 1 phosphate receptor (s1pr) modulator drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for sphingosine 1 phosphate receptor (s1pr) modulator drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sphingosine 1 phosphate receptor (s1pr) modulator drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Fingolimod; Ozanimod
- 2) By Route Of Administration: Oral; Injectable; Topical
- 3) By Application: Multiple Sclerosis; Cardiovascular Diseases; Transplant Rejection
- 4) By End User: Hospital; Rehabilitation Centres; Retail Pharmacies
- Subsegments:
- 1) By Fingolimod: Branded Formulations; Generic Formulations
- 2) By Ozanimod: Oral Capsules; Other Formulations
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bristol Myers Squibb Company; Novartis International AG; Biogen Inc.; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Ono Pharmaceutical Co. Ltd.; Actelion Pharmaceuticals Ltd.; KYORIN Pharmaceutical Co. Ltd.; Vanda Pharmaceuticals Inc.; Celgene Corporation; Ventyx Biosciences Inc.; Idorsia Pharmaceuticals Ltd.; Cayman Chemical Company; Juvise Pharmaceuticals; Priothera Limited; Arena Pharmaceuticals.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Characteristics
3. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Trends And Strategies
4. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Growth Rate Analysis
- 5.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Total Addressable Market (TAM)
6. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Segmentation
- 6.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fingolimod
- Ozanimod
- 6.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- Topical
- 6.3. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Multiple Sclerosis
- Cardiovascular Diseases
- Transplant Rejection
- 6.4. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Rehabilitation Centres
- Retail Pharmacies
- 6.5. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Fingolimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Branded Formulations
- Generic Formulations
- 6.6. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Sub-Segmentation Of Ozanimod, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Capsules
- Other Formulations
7. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Regional And Country Analysis
- 7.1. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 8.1. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 9.1. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 9.2. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 10.1. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 11.1. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 11.2. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 12.1. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 13.1. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 14.1. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 14.2. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 15.1. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 15.2. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 16.1. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 17.1. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 18.1. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 19.1. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 20.1. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 21.1. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 21.2. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 22.1. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 23.1. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 23.2. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 24.1. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 24.2. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 25.1. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 25.2. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 26.1. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 26.2. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 27.1. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 28.1. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 28.2. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
- 29.1. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Overview
- 29.2. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape And Company Profiles
- 30.1. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Landscape
- 30.2. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Other Major And Innovative Companies
- 31.1. Novartis International AG
- 31.2. Biogen Inc.
- 31.3. Eisai Co. Ltd.
- 31.4. Sun Pharmaceutical Industries Ltd.
- 31.5. Ono Pharmaceutical Co. Ltd.
- 31.6. Actelion Pharmaceuticals Ltd.
- 31.7. KYORIN Pharmaceutical Co. Ltd.
- 31.8. Vanda Pharmaceuticals Inc.
- 31.9. Celgene Corporation
- 31.10. Ventyx Biosciences Inc.
- 31.11. Idorsia Pharmaceuticals Ltd.
- 31.12. Cayman Chemical Company
- 31.13. Juvise Pharmaceuticals
- 31.14. Priothera Limited
- 31.15. Arena Pharmaceuticals
32. Global Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
34. Recent Developments In The Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market
35. Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Sphingosine 1 Phosphate Receptor (S1PR) Modulator Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
